A Phase II study with FOL-005 for treatment of Alopecia approved by the German Medicines Agency
Follicum AB (“Follicum” or “the Company”) today announces that it has received approval from the German Medicines Agency (BfArM) and the German Ethics Committee to start a Phase IIa clinical study with a topical formulation of FOL-005 on patients with alopecia (hair